Product Description
An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cerdulatinib)
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Follicular Lymphoma|T-Cell Peripheral Lymphoma
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|T-Cell Leukemia|Lymphoma, B-Cell|T-Cell Peripheral Lymphoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Vitiligo
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CELTIC-1 | P3 |
Withdrawn |
T-Cell Peripheral Lymphoma|Follicular Lymphoma |
2022-12-31 |
50% |
NCT01994382 | P2 |
Completed |
Lymphoma, B-Cell|T-Cell Peripheral Lymphoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|T-Cell Leukemia|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia |
2020-12-15 |
|
DMVT-502-2101 | P2 |
Completed |
Vitiligo |
2020-11-03 |
48% |
NCT04757259 | N/A |
No longer available |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
None |